<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117660</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001620</org_study_id>
    <secondary_id>R01GM124264-01</secondary_id>
    <nct_id>NCT03117660</nct_id>
  </id_info>
  <brief_title>Effects of Retinoids on CYP2D6 Activity During Pregnancy</brief_title>
  <official_title>Effects of Retinoids on CYP2D6 Activity and Variability in Special Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective drug interaction study during pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized pharmacokinetic study to evaluate CYP2D6 activity with and without vitamin A&#xD;
      administration during pregnancy and compared to postpartum control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Anticipated">April 24, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 24, 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, parallel group study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CYP2D6 activity: dextromethorphan metabolic ratio</measure>
    <time_frame>4 weeks</time_frame>
    <description>dextromethorphan metabolic ratio change from baseline during pregnancy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>CYP2D6 Polymorphism</condition>
  <arm_group>
    <arm_group_label>Vitamin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 3-4weeks of vitamin A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will receive no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin A</intervention_name>
    <description>vitamin A daily X3-4 weeks</description>
    <arm_group_label>Vitamin A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancies&#xD;
&#xD;
          -  Extensive metabolizers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic or persistent cough accompanying asthma, smoking or chronic obstructive&#xD;
             pulmonary disease&#xD;
&#xD;
          -  Productive cough&#xD;
&#xD;
          -  Fever&#xD;
&#xD;
          -  Known kidney disease&#xD;
&#xD;
          -  Known liver disease&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Obesity&#xD;
&#xD;
          -  Bipolar disease&#xD;
&#xD;
          -  Attention deficit disorder&#xD;
&#xD;
          -  Social phobia&#xD;
&#xD;
          -  Allergy or history of adverse event with dextromethorphan&#xD;
&#xD;
          -  Drugs, foods, beverages or dietary supplements that interact with CYP2D6 or&#xD;
             dextromethorphan&#xD;
&#xD;
          -  dextromethorphan&#xD;
&#xD;
          -  Unable to give written informed consent&#xD;
&#xD;
          -  Inability to fast&#xD;
&#xD;
          -  Concurrent use of vitamin A supplementation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnancy study</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary F Hebert, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Mary Hebert</investigator_full_name>
    <investigator_title>Professor of Pharmacy, Adjunct Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators will adhere to the NIH Grant Policy on Sharing Research Data. That is, after final data collection and analysis and after full peer review is performed on the data, the de-identified data generated by this project will be made available when requested by the academic community and researchers-at-large contingent upon Material Transfer Agreements with the University of Washington.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

